Ignite Creation Date:
2025-12-24 @ 12:02 PM
Ignite Modification Date:
2026-02-25 @ 8:16 PM
Study NCT ID:
NCT02588261
Status:
TERMINATED
Last Update Posted:
2024-12-10
First Post:
2015-10-26
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
Sponsor:
Astellas Pharma Global Development, Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Non-small Cell Lung Cancer (NSCLC) | View |